NCT05957536View on ClinicalTrials.gov

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

March 11, 2026

Study Completion Date

March 11, 2026

Conditions
HER-2 Positive Advanced Solid Tumors
Interventions
BIOLOGICAL

D3L-001

Intravenous administration

Trial Locations (9)

2109

RECRUITING

D3 Bio Investigative Site, Sydney

3144

RECRUITING

D3 Bio Investigative Site, Malvern

10065

RECRUITING

D3 Bio Investigative Site, New York

78229

TERMINATED

D3 Bio Investigative Site, San Antonio

94305

RECRUITING

D3 Bio Investigative Site, Stanford

150088

RECRUITING

D3 Bio Investigative Site, Harbin

200025

RECRUITING

D3 Bio Investigative Site, Shanghai

310022

RECRUITING

D3 Bio Investigative Site, Hangzhou

02215

RECRUITING

D3 Bio Investigative Site, Boston

All Listed Sponsors
lead

D3 Bio (Wuxi) Co., Ltd

INDUSTRY